Peregrine flying high as CMO biz preps to open new mAb facility

By Dan Stanton contact

- Last updated on GMT

Peregrine's CMO subsidiary, Avid Bioservices, is located in Tustin, California
Peregrine's CMO subsidiary, Avid Bioservices, is located in Tustin, California

Related tags: Lung cancer

Avid Bioservices' expansion will double existing capacity to service both a $40m backlog and its owner Peregrine, which is hoping to commercialise its breast cancer candidate.

Peregrine Pharmaceuticals saw revenues grow 20% y-o-y, mostly due to its contract manufacturing subsidiary Avid Biosciences which reported total sales of $27m (€25m) for the fiscal year 2015.

During a conference call discussing these results Tuesday, management said there was a committed backlog of $40m from existing customers, much of which will be carried out at a new mammalian cell culture facility in California set to come online in the next few months.

Last December​, we laid out strategic plans to expand our manufacturing capacity to help support the revenue growth of Avid,”​ said CFO Paul Lytle. “I am excited to say that the new facility is close to being ready for production​.

“The core manufacturing suite has been built, the equipment has been installed, and it is now undergoing some final testing to ensure all systems are operating effectively,”​ he told investors. “We remain on track to commence production in this new facility in the very near future.”

While the investment will service its customers, the facility has also been built in preparation of a commercial launch of Peregrine’s own lead candidate bavituximab a monoclonal antibody (mAb) for non-small cell lung cancer (NSCLC), a Phase III trial blinded, randomized trial of which is on track to end enrolment by the end of the year.

The new facility was described as a “pivotal event”​ in the growth of Avid and potential commercialization of bavituximab by CEO Steve King during the call, who added there would be “a nice mix”​ between in-house and customer utilization.

Related topics: Contract Manufacturing, Phase III-IV

Related news

Show more

Related products

show more


Lyophilization Scale-Up and Tech Transfer

Baxter BioPharma Solutions | 12-Mar-2018 | Technical / White Paper

There are few challenges when increasing the scale of production for a solution formulation, but the challenges drastically increase when the formulation...

How will Brexit affect the Pharmaceutical Industry?

How will Brexit affect the Pharmaceutical Industry?

Source BioScience Ltd | 08-Mar-2018 | Technical / White Paper

Have you prepared your strategy for the outcome of Brexit to ensure that you can continue to supply the UK market?
Source BioScience is a CRO with...

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

Related suppliers